<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827788</url>
  </required_header>
  <id_info>
    <org_study_id>Arezzo001</org_study_id>
    <secondary_id>EUDRACT 2008-008491-13</secondary_id>
    <nct_id>NCT00827788</nct_id>
  </id_info>
  <brief_title>Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)</brief_title>
  <acronym>CONTRAST-AMI</acronym>
  <official_title>The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Le Scotte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale della Misericordia - Grosseto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence of contrast induced nephropathy and
      myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide
      administration in patients with acute myocardial infarction undergoing primary PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric randomized comparison between iso-osmolar and ipo-osmolar contrast
      agents in patients treated with primary PCI with the evaluation of contrast-induced
      nephropathy incidence and myocardial tissue reperfusion. The study was designed as a
      non-inferiority trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Contrast Induced Nephropathy (CIN) between the two study groups, defined as relative increase of serum Creatinine of 25% or more from basal values</measure>
    <time_frame>days 1, 2, 3, and at discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI grade flow</measure>
    <time_frame>before and after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TFC (TIMI frame count)</measure>
    <time_frame>after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMPG (TIMI Myocardial Perfusion Grade)</measure>
    <time_frame>after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LFR slope (load to function slope)</measure>
    <time_frame>after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>1, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute increase in serum Creatinine</measure>
    <time_frame>days 1, 2, 3, and at discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative increase in serum creatinine of 50% or more</measure>
    <time_frame>days 1, 2, 3, and at discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>iodixanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iso-osmolar contrast medium (Iodixanol) will be administered during PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iopromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-osmolar contrast medium (Iopromide) will be administered during PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol</intervention_name>
    <description>Iso-osmolar contrast medium (Iodixanol) will be administered during PCI</description>
    <arm_group_label>iodixanol</arm_group_label>
    <other_name>Visipaque®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iopromide</intervention_name>
    <description>Low-osmolar contrast medium (Iopromide) will be administered during PCI</description>
    <arm_group_label>iopromide</arm_group_label>
    <other_name>Ultravist®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged ≥ 18

          -  Patients with ST-elevation Myocardial Infarction presenting within 12 hours after the
             onset of symptoms (18 hours in case of cardiogenic shock), who are scheduled to
             undergo primary PCI

          -  Patients who have signed and dated the written informed consent form

        Exclusion Criteria:

          -  Patients in pregnancy or lactation

          -  Long-term dialysis

          -  Administration of any investigational drug within the previous 30 days

          -  Intra-arterial or intravenous administration of iodinated contrast medium from 7 days
             before to 72 hours after the administration of study drug

          -  Intake of any nephrotoxic medications 24 hours before or after the administration of
             study drug

          -  Contraindications to the study drug or the cardiac catheterization procedure

          -  Previous participation in this study

          -  As the discretion of the investigator, the patient has any conditions not appropriate
             to the usage of iodinated contrast agent or not appropriate to undergo cardiac
             catheterization procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Bolognese, MD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale SanDonato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Department, Ospedale S.Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>November 15, 2010</last_update_submitted>
  <last_update_submitted_qc>November 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cardiovascular Department USL 8(Leonardo Bolognese MD)</name_title>
    <organization>Ospedale SanDonato</organization>
  </responsible_party>
  <keyword>contrast media</keyword>
  <keyword>angiography</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

